Navigation Links
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Date:4/16/2008

NEW YORK, April 16 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the Annual Meeting of the AACR in San Diego today. The company presented data in the experimental therapeutics session on NXD30001, one of several novel, radicicol-based Hsp90 inhibitors in its compound series.

NXD30001 demonstrated efficacy in breast cancer tumor xenograft models without evidence for liver and kidney toxicity. The potency, tolerability, pharmacokinetic and pharmacodynamic properties of NXD30001 and its derivatives indicate that it, or an analog, may be useful in the treatment of breast and other forms of cancer with an improved dosing and therapeutic window compared to 17AAG, the first-in-class Hsp90 inhibitor currently in Phase 2 clinical trials for cancer.

The compound series appears to bind Hsp90 in a different mode than 17AAG or radicicol and exhibit higher affinity to Hsp90 than radicicol. NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, Akt, c-Raf, Cdk4, and Cyclin D1 in Her2-overexpressing breast and other cancer cell lines at low nanomolar concentrations. Pharmacokinetic studies demonstrate that NXD30001 can achieve potential therapeutic levels via intraperitoneal (i.p.) dosing and that the compound accumulates in tumors at above micromolar concentrations.

Tumor pharmacodynamic analysis demonstrated depletion of multiple Hsp90 client proteins, including Her2, after a single dose; these client proteins remained undetectable for more than 2 days, consistent with the pharmacokinetic tumor data.

"A number of analogs with activity similar to or better than NXD30001 have been synthesized and are being evaluated for oral bioavailability, tolerability, and efficacy," stated Allan Rubenstein, MD, CEO of NexGenix. "Our intent is to progress an i.v. formulation of NXD30001 into IND-enabling studies for breast cancer, and to develop
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... down the product choices to a manageable shortlist of bench and floor scales ... models that fit best with the customer’s industry and application. , Side-by-side ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, ... second US laboratory is to open in Manhattan, Kansas in early October, 2015. ... long-term growth of research and development through collaboration with researchers from Kansas State ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... Innovator in Pharmaceutical Thin Film,Technology -, WARREN, ... delivery,company specializing in quick dissolving thin film pharmaceutical ... patent No. 7,425,292 from the,United States Patent and ... expected to issue on September 16, 2008, relates,to ...
... Inc. is,pleased to announce the release of TreatmentTrends(TM): Anemia ... with Anemia Managers. It is,based on the results of ... working with dialysis patients and 50 working with later ... a,subset of 25 respondents. The report focuses on the ...
... Sept. 11 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... quarter and year-end financial results on September,16, 2008., ... its financial results.,Details for the fiscal year-end call are ... 2008 -- Time: 10:30 a.m. ET, 9:30 a.m. ...
Cached Biology Technology:MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 2MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 3New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices 2New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices 3Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... of ASU researchers led by Nongjian Tao and Peiming Zhang ... DNA mutations. , Their results, published in the journal Proceedings ... time, the possibility of directly identifying these mutations, or single ... of a single DNA molecule. , SNPs are buried ...
... Oregon State University have made a major discovery in basic ... in plant genetics or biotechnology. , The scientists have identified ... cell membranes, where it functions as a toxin to kill ... can penetrate cell wall barriers and disrupt plant cells, but ...
... antiretroviral therapy for HIV slashed in poorer countries. But a ... these complex treatments remains a stumbling block. , Now ... solution: a hand-held sensor that checks the health of a ... take a week to get the same results back from ...
Cached Biology News:ASU researchers 'wire' DNA to identify mutations 2ASU researchers 'wire' DNA to identify mutations 3Biologists discover new pathway into plant cells 2Biologists discover new pathway into plant cells 3Cheap, rapid hand-held check for HIV 2
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Catalase (Control)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: